22:46 , Jan 5, 2018 |  BC Week In Review  |  Company News

Array spins out Yarra to develop ARRY-797

Array BioPharma Inc. (NASDAQ:ARRY) spun out Yarra Therapeutics LLC (Boulder, Colo.) to develop ARRY-797. In 2016, Array reported data from a Phase II trial in patients with symptomatic dilated cardiomyopathy due to a lamin A/C...
07:00 , Sep 12, 2016 |  BC Week In Review  |  Clinical News

ARRY-371797: Phase II data

An open-label, U.S. Phase II trial in 9 evaluable patients with symptomatic dilated cardiomyopathy due to an LMNA gene mutation showed that twice-daily oral ARRY-797 improved mean 6MWT distance from baseline to 12 weeks by...
07:00 , May 12, 2014 |  BC Week In Review  |  Clinical News

ARRY-371797: Phase II started

Array began an open-label, U.S. Phase II trial to evaluate 2 dose levels of oral ARRY-797 for 48 weeks in about 12 patients with symptomatic DCM due to an LMNA gene mutation. ARRY-797 has also...
00:32 , Jun 6, 2013 |  BC Extra  |  Financial News

Array raises $115M in note deal

Array BioPharma Inc. (NASDAQ:ARRY) raised $115 million through the sale of 3% unsecured senior convertible notes due June 1, 2020. The notes initially convert at $7.05, a 22% premium to Array's close of $5.78 on...
01:54 , Nov 10, 2012 |  BC Extra  |  Financial News

Array raises $65.7 million in follow-on

Array BioPharma Inc. (NASDAQ:ARRY) raised $65.7 million through the sale of 18 million shares at $3.65 in a follow-on underwritten by Jefferies; JPMorgan; Piper Jaffray; Stifel Nicolaus Weisel; and William Blair. Array has three products...
01:41 , Nov 9, 2012 |  BC Extra  |  Financial News

Array proposes follow-on

Array BioPharma Inc. (NASDAQ:ARRY) said late Thursday it is planning a follow-on underwritten by Jefferies; JPMorgan; Piper Jaffray; Stifel Nicolaus Weisel; and William Blair. Array has several products in Phase II testing including ARRY-520, a...
07:00 , Aug 6, 2012 |  BC Week In Review  |  Clinical News

ARRY-797: Phase II data

A double-blind, U.S. Phase II trial in 157 patients with OA of the knee who had moderate to severe chronic pain despite NSAID use showed that twice-daily 400 mg oral ARRY-797 met the primary endpoint...
00:27 , Aug 1, 2012 |  BC Extra  |  Clinical News

Array's ARRY-797 meets Phase II pain endpoint

Array BioPharma Inc. (NASDAQ:ARRY) said oral ARRY-797 met the primary endpoint of reducing mean WOMAC pain subscale scores from baseline to day 28 vs. placebo in a Phase II trial to treat osteoarthritis (OA) of...
01:19 , Feb 10, 2012 |  BC Extra  |  Financial News

Array raises $52 million

Array BioPharma Inc. (NASDAQ:ARRY) raised $52 million through the sale of 20 million shares at $2.60 in a follow-on underwritten by Jefferies; Leerink; and Stifel Nicolaus Weisel. Array proposed the offering late Wednesday, when its...
02:14 , Feb 9, 2012 |  BC Extra  |  Financial News

Array, Apricus planning follow-ons

Array BioPharma Inc. (NASDAQ:ARRY) and Apricus Biosciences Inc. (NASDAQ:APRI) each said late Wednesday they are planning follow-ons. Jefferies; Leerink; and Stifel Nicolaus Weisel are underwriting Array's offering, while Lazard is underwriting Apricus' offering. Array has...